MERTK and breast cancer: Since miR‐335 was shown to be down‐regulated in aggressive CRC and breast cancer (Tavazoie et al, 2008; Sun et al, 2014), one could speculate that aberrant expression of MERTK in CRC may be due to down‐regulation of miR‐335.